Raphael Korach

Raphael Korach

Auto-generated profile, based on publicly available information

Raphael Korach

Division of Nephrology, University Hospital Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
DHDusan Harmacek
Dusan Harmacek
LWLukas Weidmann
Lukas Weidmann
KLKai Castrezana Lopez
Kai Castrezana Lopez
NSNicolas Schmid
Nicolas Schmid
RKRaphael Korach
Raphael Korach
TSThomas Schachtner
Thomas Schachtner
Biopsy-based transcript diagnostics may identify molecular antibody-mediated rejection (AMR) when microvascular inflammation (MVI) is absent. In this single-center cohort, biopsy-based transcript diagnostics were validated in 326 kidney allograft biopsies. 71 histological AMR and 35 T-cell mediated rejection (TCMR) cases were identified as molecular AMR and TCMR in 55% and 63%, respectively. Among 121 cases without MVI (g+ptc=0), 45 donor-specific antibody (DSA)-positive (37%) and 76 DSA-negative cases (63%) were analyzed. 21/121 (17%) cases showed borderline changes or TCMR, while BK nephropathy was excluded. None of the 45 DSA-positive patients showed molecular AMR. Among 76 DSA-negative patients, two had mixed molecular AMR/TCMR. The all AMR phenotype score (sum of R4-R6) exhibited median values of 0.13 and 0.12 for DSA-positive and DSA-negative patients, respectively (p=0.84). 6/45 (13%) DSA-positive and 8/76 (11%) DSA-negative patients showed an all AMR phenotype score >0.30 (p=0.77). Patients with a higher all AMR phenotype score showed 33% more histological TCMR (p=0.005). The median all AMR phenotype scores of glomerular basement membrane double contours (cg)=0 and cg>0 biopsies were 0.12 and 0.10, respectively (p=0.35). Biopsy-based transcript diagnostics did not identify molecular AMR in cases without MVI. Follow-up biopsies and outcome data should evaluate the clinical relevance of sub-threshold molecular alterations.